Please assess the completion status of the following clinical trial:

Trial Title: Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~HIV positive patients over 18 years old, who have failed first-line ART regimen of tenofovir-emtricitabine/lamivudine-efavirenz, are able to attend the study clinic for one year of scheduled visits and who have given written, informed consent will be enrolled in this study. In female patients of child-bearing potential, those willing to use effective and reliable contraception for the duration of the study will be eligible.~Failure of a first-line regimen is defined as a viral load (VL) of \>1000 copies/mL (within the previous two months) and an immediately prior VL \>1000 copies/mL, taken 2-24 months prior (based on data captured by National Health Laboratory Service).~Exclusion Criteria:~* If the patient has two VLs 2-3 months apart: \>2 log drop in VLs between the most recent VL (within the previous two months) and the immediately prior VL (taken 2-3 months prior)~* CD4 count \<100 cells/microlitre~* Estimated glomerular filtration rate (eGFR) \<50 mL/min/1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula~* Alanine aminotransferase \>100 U/L or total bilirubin \>twice the upper limit of normal~* Pregnant or desire to become pregnant during the study period (48 weeks)~* Breastfeeding~* Being treated for active tuberculosis (TB) or concern that patient has undiagnosed active TB (based on symptom screening) as rifampicin reduces the concentrations of dolutegravir and thus requires dose adjustments~* Any current diagnosis of malignancy~* Allergy or intolerance to one of the drugs in regimen~* Active, severe psychiatric disease judged likely to impact adherence~* Current substance abuse judged likely to impact adherence~* On treatment for AIDS-defining condition (not including secondary prophylaxis maintenance therapy)~* Any other clinical condition that in the opinion of an investigator puts the patient at increased risk if participating in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supplementary dose (Type: ACTIVE_COMPARATOR): Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later for the first 14 days.
- Placebo dose (Type: PLACEBO_COMPARATOR): Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet daily with a matching placebo taken 12 hours later for the first 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).